Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10485673 | 0.83 | APP (0.64) | APPCDK1NPSR1CHUKSMN1; SMN2 | |
| SCHEMBL3391705 | 0.81 | APP (0.61) | APPNPSR1PDE5AEGFR | |
| SCHEMBL4926850 | 0.80 | MAPT (0.66) | APPNPSR1SMN1; SMN2 | |
| SCHEMBL13244946 | 0.80 | APP (0.52) | APPCDK1PLAUNPSR1PDE5A | |
| SCHEMBL9476148 | 0.79 | MEN1 (0.48) | APPSMN1; SMN2 | |
| SCHEMBL3396367 | 0.79 | PLAU (0.53) | PLAUPDE5ASMN1; SMN2 | |
| SCHEMBL4045936 | 0.79 | EGFR (0.53) | APPPDE5AEGFR | |
| SCHEMBL783719 | 0.77 | KDM4C (0.72) | EGFRSMN1; SMN2 | |
| SCHEMBL30983851 | 0.77 | KDM4C (0.72) | EGFRSMN1; SMN2 | |
| SCHEMBL18207827 | 0.77 | SRC (0.50) | APPPLAUPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7129244-B2 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | APP 4604/4885CDK1 563/4885PLAU 4571/4885 |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | APP 4604/4885CDK1 563/4885PLAU 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.